Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40


Clear up this stem-cell mess.

Sipp D, Robey PG, Turner L.

Nature. 2018 Sep;561(7724):455-457. doi: 10.1038/d41586-018-06756-9. No abstract available.


Challenges in the Regulation of Autologous Stem Cell Interventions in the United States.

Sipp D.

Perspect Biol Med. 2018;61(1):25-41. doi: 10.1353/pbm.2018.0025.


The malignant niche: safe spaces for toxic stem cell marketing.

Sipp D.

NPJ Regen Med. 2017 Dec 19;2:33. doi: 10.1038/s41536-017-0036-x. eCollection 2017. Review.


Identity and ownership issues in the regulation of autologous cells.

Sipp D.

Regen Med. 2017 Oct;12(7):827-838. doi: 10.2217/rme-2017-0063. Epub 2017 Nov 8.


Marketing of unproven stem cell-based interventions: A call to action.

Sipp D, Caulfield T, Kaye J, Barfoot J, Blackburn C, Chan S, De Luca M, Kent A, McCabe C, Munsie M, Sleeboom-Faulkner M, Sugarman J, van Zimmeren E, Zarzeczny A, Rasko JEJ.

Sci Transl Med. 2017 Jul 5;9(397). pii: eaag0426. doi: 10.1126/scitranslmed.aag0426. Review.


Ethical and Regulatory Challenges with Autologous Adult Stem Cells: A Comparative Review of International Regulations.

Lysaght T, Kerridge IH, Sipp D, Porter G, Capps BJ.

J Bioeth Inq. 2017 Jun;14(2):261-273. doi: 10.1007/s11673-017-9776-y. Epub 2017 Feb 28. Review.


Global Distribution of Businesses Marketing Stem Cell-Based Interventions.

Berger I, Ahmad A, Bansal A, Kapoor T, Sipp D, Rasko JEJ.

Cell Stem Cell. 2016 Aug 4;19(2):158-162. doi: 10.1016/j.stem.2016.07.015.


Cell Churches and Stem Cell Marketing in South Korea and the United States.

Sipp D.

Dev World Bioeth. 2017 Dec;17(3):167-172. doi: 10.1111/dewb.12120. Epub 2016 May 23.


Policy: Global standards for stem-cell research.

Kimmelman J, Hyun I, Benvenisty N, Caulfield T, Heslop HE, Murry CE, Sipp D, Studer L, Sugarman J, Daley GQ.

Nature. 2016 May 19;533(7603):311-3. doi: 10.1038/533311a. No abstract available.


Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines.

Daley GQ, Hyun I, Apperley JF, Barker RA, Benvenisty N, Bredenoord AL, Breuer CK, Caulfield T, Cedars MI, Frey-Vasconcells J, Heslop HE, Jin Y, Lee RT, McCabe C, Munsie M, Murry CE, Piantadosi S, Rao M, Rooke HM, Sipp D, Studer L, Sugarman J, Takahashi M, Zimmerman M, Kimmelman J.

Stem Cell Reports. 2016 Jun 14;6(6):787-797. doi: 10.1016/j.stemcr.2016.05.001. Epub 2016 May 12.


SCIENTIFIC COMMUNITY. Confronting stem cell hype.

Caulfield T, Sipp D, Murry CE, Daley GQ, Kimmelman J.

Science. 2016 May 13;352(6287):776-7. doi: 10.1126/science.aaf4620. Epub 2016 May 12. No abstract available.


Undertested and Overpriced: Japan Issues First Conditional Approval of Stem Cell Product.

McCabe C, Sipp D.

Cell Stem Cell. 2016 Apr 7;18(4):436-7. doi: 10.1016/j.stem.2016.03.006. No abstract available.


Paolo Bianco (1955-2015).

Robey PG, Riminucci M, Boyde A, Sipp D.

Cell Stem Cell. 2015 Dec 3;17(6):649-50. No abstract available.


Conditional approval: Japan lowers the bar for regenerative medicine products.

Sipp D.

Cell Stem Cell. 2015 Apr 2;16(4):353-6. doi: 10.1016/j.stem.2015.03.013.


Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI).

Andrews PW, Baker D, Benvinisty N, Miranda B, Bruce K, Brüstle O, Choi M, Choi YM, Crook JM, de Sousa PA, Dvorak P, Freund C, Firpo M, Furue MK, Gokhale P, Ha HY, Han E, Haupt S, Healy L, Hei DJ, Hovatta O, Hunt C, Hwang SM, Inamdar MS, Isasi RM, Jaconi M, Jekerle V, Kamthorn P, Kibbey MC, Knezevic I, Knowles BB, Koo SK, Laabi Y, Leopoldo L, Liu P, Lomax GP, Loring JF, Ludwig TE, Montgomery K, Mummery C, Nagy A, Nakamura Y, Nakatsuji N, Oh S, Oh SK, Otonkoski T, Pera M, Peschanski M, Pranke P, Rajala KM, Rao M, Ruttachuk R, Reubinoff B, Ricco L, Rooke H, Sipp D, Stacey GN, Suemori H, Takahashi TA, Takada K, Talib S, Tannenbaum S, Yuan BZ, Zeng F, Zhou Q.

Regen Med. 2015;10(2 Suppl):1-44. doi: 10.2217/rme.14.93. No abstract available.


Enabling consistency in pluripotent stem cell-derived products for research and development and clinical applications through material standards.

French A, Bravery C, Smith J, Chandra A, Archibald P, Gold JD, Artzi N, Kim HW, Barker RW, Meissner A, Wu JC, Knowles JC, Williams D, García-Cardeña G, Sipp D, Oh S, Loring JF, Rao MS, Reeve B, Wall I, Carr AJ, Bure K, Stacey G, Karp JM, Snyder EY, Brindley DA.

Stem Cells Transl Med. 2015 Mar;4(3):217-23. doi: 10.5966/sctm.2014-0233. Epub 2015 Feb 3. Review.


Oversight for clinical uses of autologous adult stem cells: lessons from international regulations.

Lysaght T, Kerridge I, Sipp D, Porter G, Capps BJ.

Cell Stem Cell. 2013 Dec 5;13(6):647-51. doi: 10.1016/j.stem.2013.11.013.


The implementation of novel collaborative structures for the identification and resolution of barriers to pluripotent stem cell translation.

Brindley DA, French A, Suh J, Roberts M, Davies B, Pinedo-Villanueva R, Wartolowska K, Rooke K, Kramm A, Judge A, Morrey M, Chandra A, Hurley H, Grover L, Bingham I, Siegel B, Rattley MS, Buckler RL, McKeon D, Krumholz K, Hook L, May M, Rikabi S, Pigott R, Morys M, Sabokbar A, Titus E, Laabi Y, Lemaitre G, Zahkia R, Sipp D, Horne R, Bravery C, Williams D, Wall I, Snyder EY, Karp JM, Barker RW, Bure K, Carr AJ, Reeve B.

Stem Cells Dev. 2013 Dec;22 Suppl 1:63-72. doi: 10.1089/scd.2013.0403.


Global bionetworks and challenges in regulating autologous adult stem cells.

Lysaght T, Kerridge I, Sipp D, Porter G, Capps BJ.

Am J Med. 2013 Nov;126(11):941-3. doi: 10.1016/j.amjmed.2013.06.031. No abstract available.


Tissue interactions in neural crest cell development and disease.

Takahashi Y, Sipp D, Enomoto H.

Science. 2013 Aug 23;341(6148):860-3. doi: 10.1126/science.1230717. Review.


Supplemental Content

Loading ...
Support Center